Agree To Buy HCA Healthcare At $350, Earn 5.6% Using Options

An analysis of HCA Healthcare Inc. highlights the potential for selling a September 2026 put option at a $350 strike to generate a 5.2% annualized return, significantly outperforming the stock's 0.7% dividend yield. This strategy offers a substantial premium and a 14.8% downside buffer before potential assignment, though it caps upside to the premium received. The discussion comes as S&P 500 options data indicates a higher-than-normal put-to-call ratio of 0.71, suggesting increased hedging or bearish sentiment in the broader market.

Analysis

An analysis of HCA Healthcare Inc. (HCA) reveals a specific options strategy involving the sale of a September 2026 put option with a $350 strike price. This strategy generates a 5.2% annualized rate of return from the collected premium, which is notably 4.5 percentage points higher than the stock's current 0.7% annualized dividend yield. The trade structure provides a significant downside buffer, as the put seller would only be assigned shares if HCA's stock price, currently at $409.87, declines by 14.8% to the strike price. In the event of assignment, the effective cost basis for the shares would be $330.30, factoring in the $19.70 premium received. However, this income-generating strategy forgoes any potential stock price appreciation beyond the premium. The decision to execute such a trade should be weighed against the stock's trailing twelve-month volatility of 28%. Contextually, this analysis comes as the broader market exhibits some caution, evidenced by an S&P 500 put:call ratio of 0.71, which is elevated compared to the long-term median of 0.65, suggesting an increase in hedging or bearish sentiment.

Key Decisions for Investors

• For income-focused investors, selling the HCA September 2026 $350 put offers a compelling 5.2% annualized yield, but requires an acceptance of the stock ownership obligation if the price falls below the strike.
• Investors with a strong bullish outlook on HCA should recognize this strategy forfeits all capital appreciation upside, making direct stock ownership a more suitable approach to capture potential gains.
• Traders must evaluate their willingness to acquire HCA shares at an effective cost of $330.30, considering the stock's 28% historical volatility and the 14.8% price decline required to trigger assignment.
• The elevated put-to-call ratio in the broader market may warrant consideration of defensive, premium-generating strategies that offer a downside cushion, such as the one described for HCA.